MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1505)	7/16/2004 2:47:45 PM
From: Icebrg	of 1826

MGI Pharma "market outperform," estimates raised Friday, July 16, 2004 2:48:02 AM ET JMP Securities NEW YORK, July 16 (New Ratings) - Analyst Howard Liang of JMP Securities maintains his "market outperform" rating on MGI Pharma Inc (MOGN.NAS), while raising his estimates for the company. The target price is set to $37. In a research note published yesterday, the analyst mentions that the company declared healthy 2Q04 results, with EPS and sales significantly ahead of the estimates and the consensus. The analysts believe that the company has significant near term growth potential due to its impressive clinical profile, despite the impending changes in Medicare reimbursement. The EPS estimates for 2004 and 2005 have been raised from $0.30 to $0.51 and from $0.77 to $0.92, respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next